Moxifloxacin – Fluoroquinolone for “Special Tasks” in Ophthalmology
Wydanie 4/2023
str. 57–59
Autor: Ewelina Trojacka1, Justyna Izdebska1,2,3
1 Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie – Kierownik: prof. dr hab. n. med. Jacek P. Szaflik
2 Katedra i Klinika Okulistyki Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego – Kierownik: prof. dr hab. n. med. Jacek P. Szaflik
3 Centrum Mikrochirurgii Oka LASER w Warszawie
Summary:
Moxifloxacin is a broad spectrum chemotherapeutic that belongs to fourth generation of fluoroquinolones. It acts bactericidal against Gram positive and Gram negative bacteria. Modified structure of moxifloxacin molecule is responsible for improved pharmacokinetics and lower risk of developing resistance. It is intended for advanced, sight‑threatening infections that do not respond to older fluoroquinolones. Moxifloxacin, administered in a form of an intracameral injection during cataract phacoemulsification, is used as a prophylaxis against postoperative endophthalmitis.